KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Long-Term Deferred Tax: 2009-2024

Historic Long-Term Deferred Tax for Alnylam Pharmaceuticals (ALNY) over the last 4 years, with Dec 2024 value amounting to $116.9 million.

  • Alnylam Pharmaceuticals' Long-Term Deferred Tax was N/A to $98.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.6 million, marking a year-over-year change of. This contributed to the annual value of $116.9 million for FY2024, which is 1056.94% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Long-Term Deferred Tax of $116.9 million as of FY2024, which was up 1,056.94% from $10.1 million recorded in FY2023.
  • Alnylam Pharmaceuticals' Long-Term Deferred Tax's 5-year high stood at $116.9 million during FY2024, with a 5-year trough of $10.1 million in FY2023.
  • Over the past 2 years, Alnylam Pharmaceuticals' median Long-Term Deferred Tax value was $63.5 million (recorded in 2023), while the average stood at $63.5 million.
  • Data for Alnylam Pharmaceuticals' Long-Term Deferred Tax shows a peak YoY surged of 1,056.94% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Alnylam Pharmaceuticals' Long-Term Deferred Tax stood at $10.1 million in 2023, then surged by 1,056.94% to $116.9 million in 2024.